

# Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world

M. Million, P. Gautret, P. Colson, Y. Roussel, G. Dubourg, E. Chabriere, S. Honore, J. -M Rolain, F. Fenollar, P. -E. Fournier, et al.

# ▶ To cite this version:

M. Million, P. Gautret, P. Colson, Y. Roussel, G. Dubourg, et al.. Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world. NEW MICROBES AND NEW INFECTIONS, 2020, 38, 10.1016/j.nmni.2020.100709. hal-03149258

# HAL Id: hal-03149258 https://amu.hal.science/hal-03149258v1

Submitted on 17 Oct 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Version of Record: https://www.sciencedirect.com/science/article/pii/S2052297520300615 Manuscript\_1219dcc3788964f3ff587e5c6503d811

1	Clinical Efficacy of Chloroquine Derivatives in COVID-19 Infection: Comparative
2	Meta-analysis between the Big Data and the Real World
3	Matthieu MILLION <sup>a,b*</sup> , Philippe GAUTRET <sup>a,c*</sup> , Philippe COLSON <sup>a,b</sup> , Yanis ROUSSEL <sup>a,b</sup> ,
4	Gregory DUBOURG <sup>a,b</sup> , Eric CHABRIERE <sup>a,b</sup> , Stéphane HONORE <sup>d</sup> , Jean-Marc ROLAIN <sup>a,b</sup> ,
5	Florence FENOLLAR <sup>a,c</sup> , Pierre-Edouard FOURNIER <sup>a,c</sup> , Jean-Christophe LAGIER <sup>a,b</sup> ,
6	Philippe PAROLA <sup>a,c</sup> , Philippe BROUQUI <sup>a,b</sup> , Didier RAOULT <sup>a,b</sup>
7	<sup>a</sup> IHU-Méditerranée Infection, Marseille, France
8	<sup>b</sup> Aix Marseille Univ, IRD, AP-HM, MEPHI, Marseille, France
9	<sup>c</sup> Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France
10	<sup>d</sup> Service de Pharmacie, Hôpital Timone, AP-HM, Marseille, France; Laboratoire de
11	Pharmacie Clinique, Aix Marseille Université, Marseille, France.
12	*Equal first co-authors
13	Running title: Efficacy of Chloroquine derivatives for COVID-19 in the real world
14	Keywords: coronavirus, COVID-19, SARS-CoV-2, Hydroxychloroquine, Chloroquine, meta-
15	analysis
16	Corresponding author: Didier Raoult, IHU - Méditerranée Infection, 19-21 boulevard Jean
17	Moulin, 13005 Marseille, France. Tel.: +33 413 732 401, Fax: +33 413 732 402;

18 **E-mail**: didier.raoult@gmail.com

- **1** Clinical Efficacy of Chloroquine Derivatives in COVID-19 Infection: Comparative
  - Meta-analysis between the Big Data and the Real World
- 3 **Running title**: Efficacy of Chloroquine derivatives in COVID-19
- 4 Keywords: coronavirus, COVID-19, SARS-CoV-2, Hydroxychloroquine, Chloroquine, meta-
- 5 analysis, mortality, **Big data**, **Medical world**

#### 6 Abstract

In the context of the current COVID-19 pandemic, we conducted a meta-analysis on the 7 effects of chloroquine derivatives in patients, based on unpublished and published reports 8 available publicly on the internet as of May, 27, 2020. The keywords "hydroxychloroguine", 9 "chloroquine", "coronavirus", "COVID-19" and "SARS-Cov-2" were used in the PubMed, 10 Google Scholar and Google search engines without any restrictions as to date or language. 11 Twenty studies were identified involving 105,040 patients (19,270 treated patients) from nine 12 countries (Brazil, China, France, Iran, Saudi Arabia, South Korea, Spain, and USA). Big data 13 observational studies were associated with conflict of interest, lack of treatment dosage and 14 duration, and absence of favorable outcome. Clinical studies were associated with favorable 15 outcomes and details on therapy. Among clinical studies, three of four randomized controlled 16 trials reported a significant favorable effect. Among clinical studies, a significant favorable 17 18 summary effect was observed for duration of cough (Odds ratio (OR), 0.19, p = .00003), duration of fever (0.11, p = .039), clinical cure (0.21, p = .0495), death (0.32,  $p = 4.1 \times 10^{-6}$ ) 19 20 and viral shedding (0.43, p = .031). A trend for a favorable effect was noted for the outcome 21 "death and/or ICU transfer" (0.29, p = .069) with a point estimate remarkably similar to that observed for death (~0.3). In conclusion, a meta-analysis of publicly available clinical reports 22 demonstrates that chloroquine derivatives are effective to improve clinical and virological 23 outcomes but, more importantly, it reduces mortality by a factor 3 in patients infected with 24 COVID-19. Big data are lacking basic treatment definitions and are linked to conflict of 25

26 interest.

#### 27 Introduction

In periods of large epidemics such as the current COVID-19 pandemic, information spread very fast with different levels of reliability including fake-news, press releases, pre-prints and peer-reviewed published reports. In addition, it seems that there is a competition between lowcost generic medications that are potentially effective against SARS-CoV-2 and very expensive new drugs that are not yet approved, implying financial and organizational issues, stakeholders expectations, and administrative/policy complexity. This may lead to positions that are not only driven by science and public health.

In this context, we aimed to conduct a meta-analysis on the effects of chloroquine 35 derivatives (i.e. hydroxychloroquine (HCQ) or chloroquine (CQ)) in COVID-19 patients, 36 based on all available information from pre-prints and peer-reviewed published reports. For 37 pre-prints, we asked two reviewers of our team to provide an open review of the content 38 39 (Supplementary data) and we considered the comment of an external scientist (1). We were surprised to find major discrepancies between study conclusions ranging from dramatic 40 41 clinical improvement to dramatic increase in mortality rates under chloroquine derivative 42 treatment. We sought to understand what could explain such differences. We recently discussed the fact that it does not make sense to investigate a summary effect when 43 inconsistent studies and unexplained heterogeneity makes the average effect difficult to 44 interpret and potentially misleading (2). Thus, we first investigated the differential 45 characteristics of studies showing a very favorable effect of the treatment and of those 46 showing a clearly deleterious effect. 47

First, we found that a clear standardized protocol for treatment (3) and follow-up was detailed in studies conducted by clinicians (clinical studies), whereas it was completely lacking in studies conducted by public health experts on a large number of patients whose 51 data were extracted from electronic medical records (big data). We have already pointed out
52 the limitations of these "big data" analyses in relation with clinical inaccuracy (4).

Adequate timing (early versus delayed administration), dosage, screening of 53 contraindications, adjuvant measures and monitoring following standardized protocols are 54 critical in the benefit risk ratio of any drug against infectious diseases (3). Based on our 30-55 years' experience of treating hundreds of patients suffering Q fever endocarditis and 56 Whipple's disease with HCQ 600 mg/day (200 mg tid) (5,6), we know that this drug is 57 effective with negligible side effects when compared to the fatal outcome of both diseases. 58 Chloroquine derivatives (and paracetamol) can be used to commit suicide with overdose (7) 59 and may be fatal, at therapeutic dosage, when contraindications and adjuvant measures are not 60 carefully followed. In this context, it is expected that studies using double dose HCQ (1200 61 mg/day) in COVID-19 would be associated with toxicity (8). Accordingly, we investigated 62 63 whether a well described treatment protocol, including dosage, for at least 48 hours was associated with outcome. 64

From our seminal study (9), we observed an improved efficacy of the combination of HCQ and azithromycin (AZ) when compared to HCQ alone. A synergistic effect was confirmed by *in vitro* studies (10). This led us to change our standardized protocol by shifting from a mono-therapy to a combined therapy. This combination could not be neglected in the treatment of COVID-19 and was therefore also analyzed in the present study.

In the context of a pandemic with an unknown virus, development of new drugs is a major opportunity for "big pharma" industry, and this is potentially associated with a very high risk of conflicts of interest. This led us to consider these conflicts of interest as a moderator variable in the present work. As major financial issues are at stake, and may impact the interpretation of scientific data, we felt it was important to mention that none of us have conflict of interest with any pharmaceutical company. We performed this meta-analysis taking into account three important moderator variables: clinical studies or studies based on electronic registry data analysis (big data), studies based on a mono-therapy (chloroquine derivatives) or a combined therapy (HCQ-AZ), and finally studies where authors had potential conflicts of interest and study where authors had no conflicts of interest. In the context of the current pandemic, providing a timely and critical analysis of available data on this topic seems appropriate to us, in a public health perspective.

83

#### 84 Methods

We conducted a meta-analysis of studies evaluating the effects of chloroquine derivatives 85 against SARS-CoV-2 in groups of COVID-19 patients as compared to control groups of 86 patients who did not receive chloroquine derivatives. In these studies, groups were expected 87 88 to be similar with respect to demographics, chronic conditions, clinical presentation at enrolment and use of other antiviral drugs during the course of the disease. The keywords 89 "hydroxychloroquine", "chloroquine", "coronavirus", "COVID-19" and "SARS-Cov-2" were 90 91 used in the PubMed, Google Scholar and Google search engines without any restrictions as to date or language. Preprints were also included. Open reviews and reviewer's 92 recommendations regarding preprints are available in the supplementary data. Articles 93 published in peer-reviewed journals, pre-prints and articles available on the internet, even 94 when not published on official websites, were included. 95

The following outcomes were considered: hospitalization rate, duration of cough,
duration of fever, clinical cure, lymphocyte count, C-reactive protein level, Interleukin-6
level, thoracic CT-scan imaging, aggravation to severe, death, transfer to intensive care unit
(ICU), ventilation, length of hospital stay and persistent viral shedding as assessed by PCR.

Only studies comparing a group of COVID19 patients treated with a chloroquine
derivative to a control group without chloroquine derivatives were included. Non-comparative
(single arm) studies and studies comparing two groups treated with chloroquine derivatives at
different dosages or with different delay of treatment were excluded.

Studies were classified as "big data" studies when conducted on electronic medical 104 records extracted by public health specialists and epidemiologists who did not care COVID-105 19 patients themselves. Conversely, studies were classified as "clinical studies" when 106 107 mentioning details of treatments (dosages, duration, contraindications, monitoring...) and conducted by authors physicians (infectious diseases and internal medicine specialists, and 108 pulmonologists) who cared COVID-19 patients themselves. Conflicts of interest were 109 retrieved from author statements in the article. Another check was performed using Euros for 110 Docs (https://www.eurosfordocs.fr/) and Dollars for Docs 111

112 (https://projects.propublica.org/docdollars/) websites. We considered that there was a conflict

of interest when funding by the pharmaceutical industry exceeds  $50,000 \in$ , over seven years.

Studies were classified as "Pro", when at least one comparison reported a significant
improvement, and none were associated with a significant deleterious effect in the treated
group. Studies were classified as "Cons" when none of the comparisons reported a significant

117 favorable outcome and/or at least one comparison report a significant deleterious outcome.

118 The meta-analysis was performed with a randomized model using Comprehensive

119 Meta-Analysis v3 (Biostat, Englewood, NJ, USA) as recommended by Borenstein *et al.* (11).

120 This software made it possible to include dichotomous outcomes (number of events out of the

total) and quantitative outcomes (mean in each group, sample size, p-value). Heterogeneity

122 was considered substantial when  $I^2 > 50\%$ . A p-value < 0.05 was considered significant. A

heat map analysis was performed to test a possible clustering between Pro and Cons studies,

124 clinical and big data study design, well described treatment protocol and not described

- treatment protocol, and conflict of interest and no conflict of interest, using XLSTAT
- 126 v2020.2.2 (Addinsoft, Paris, France).

#### 129 **Results**

130 Twenty-three comparative studies were screened. Three studies were excluded because they compared two groups treated with a chloroquine derivative (delayed initiation of treatment 131 (12), high versus low dose (8), combination therapy with or without zinc (13)). As a result, 132 twenty studies were identified involving 105,040 patients (19,270 patients treated with a 133 chloroquine derivatives including 11,247 in combination with a macrolide) from nine 134 countries (Brazil, China, France, Iran, Saudi Arabia, South Korea, Spain, and USA) (Table 135 S1). The 20 studies included 8 published papers, 9 pre-prints published on MedRxiv, 1 pre-136 print published on preprints.org, and 2 available on the internet (uniform resource locator (url) 137 138 provided in Table S2). All but 2 papers in Chinese (14) and French (15) were written in English. The Chinese study (14) was translated and included. 139 We noted that registry studies based on electronic medical records did not mentioned 140 141 the dosage or included several dosages of the chloroquine derivatives used (16-20). We found that in several studies, patients used several molecules with established or potential antiviral 142 143 properties. For instance, in China and Iran, almost all patients used multiple antivirals: lopinavir/ritonavir, oseltamivir, entecavir, ribavirin, umifenovir and nebulisation of interferon 144 aerosol. In eight studies (15,18-24) patients used the combined therapy that we have 145

recommended (HCQ and AZ combination (9)). Four RCTs were included in this analysis

147 (14,25-27).

We observed major methodological pitfalls in some studies. Lymphopenia, a marker of severity (28), was significantly more frequent in the treated group in one study (17). In another study, 8 patients received HCQ in the "untreated" group (29). In this study, none of the 15 patients treated with combined therapy (HCQ + azithromycin) died or were transferred to the ICU, and the difference was significant with the untreated control group. Strikingly, this was not analyzed because it was not prespecified in the study protocol. In another work (27), all results reporting a favorable effect of HCQ in the first version of the preprint (30) on
alleviation of symptoms and C-reactive protein were removed in the final preprint version
(27) and in the published version of the article (31). Finally, the largest study that has been
done (18), is impossible to analyze because there is no notification of hospital sources or
referral to any physician. It is not known if the authors of this study saw a single patient
infected with COVID-19.

160

Big data and clinical studies were perfectly discriminated by unsupervised clustering 161 As we observed that several studies reported a clear favorable effect (15, 21-23, 25, 26, 30, 162 163 32-35) but others reported no (14,16,17,19,24,29) or a clear deleterious effect (18), we primarily performed a unsupervised clustering analysis including the following variables : 164 "Pro" / "Cons" studies, "big data" versus "clinical studies", "detailed" or "absence of detailed 165 166 treatment", presence or absence of a conflict of interest (Figure 1). In this unsupervised analysis, only the variable "big data" versus "clinical" studies 167 168 yielded to a perfect clustering. All other variables (conflict of interest, Pro / Cons, detailed treatment) did not provide a perfect clustering. We subsequently investigate whether each of 169 these parameters was significantly associated to favorable or unfavorable effect. 170 All "big data" studies reported a lack of beneficial effect of the treatment and were 171 significantly more likely associated with "Cons" variable (5/5 vs 3/15, p = .004). This was 172 also observed by examination of the meta-analysis forest plot (Figure 2, Table S3 to S8). In 173 addition, both "conflicts of interest" (p = .01) and "not described treatment protocol" 174 variables (p = .004) were associated with "Cons" variable. Conversely, clinical studies were 175 more likely to report a favorable effect of chloroquine derivatives in COVID-19 patients (p < 176 177 .05). Consistently, clinical studies with detailed treatment protocol were more likely associated with the observation of a favorable effect of the treatment (p < .05). 178

# 180 Conflict of interests are linked to a part of the biases in favor of Cons We found 4 studies with author conflicts of interest (Figure 1, Table S1). "Conflicts of 181 interest" variable was associated with big data studies (3/5 vs 1/15, p < .05) and with a 182 negative direction of treatment effect (p < 0.05, Figure 1). 183 184 The direct care or patients (clinical versus big data) explains the direction of effect 185 We primarily tested if the studies involving direct care of patients (clinical studies performed 186 by physician who took care of patients) were associated with a different direction of effect 187 compared to "big data" studies (Figure 2). The visual examination of the forest plot clearly 188 evidenced that "big data" studies reported no (16,17,19,20) or deleterious effect (18). In 189 contrast, several clinical studies reported significant favorable effects notably regarding 190 191 hospitalization rate (21), duration of fever (25,33), duration of cough (23,25), clinical cure (15,30), C-reactive protein levels (30), interleukin-6 levels (35), thoracic CT-imaging (25), 192 193 length of hospital stay (23,26), death or ICU transfer (22,32), death (34,35) and persistent 194 viral shedding (9,23,33). We compared the proportion of comparisons reporting significant differences 195 according to treatment. In the big data analyses, 4 comparisons reported a significant effect, 196 197 and all were deleterious (4/4). In the clinical studies, 17 comparisons reported a significant effect, and all were beneficial. The difference was highly significant (4/4 vs 0/17, Bilateral 198 Mid-P exact test, p = .00016). This was also supported by the significant heterogeneity 199 200 between the two subgroups (big data vs. clinical studies, mixed effect analysis, Q-value 51.8,

202

201

p ≤ .001).

# 204 Three of four randomized controlled trials reported a significant favorable effect

205 Four RCTs were included (14,25-27,30,31). All were performed in China. Three of them reported significant favorable effects. Chen Z et al. (25) reported a significant favorable effect 206 on duration of fever, duration of cough and thoracic CT-scan imaging. Huang reported a 207 significant reduction of length of hospital stay (26). Interestingly, Tang et al. (27) reported in 208 the first version of their preprint (30) a significant favorable effect on alleviation of symptoms 209 (post hoc analysis) and C-reactive protein reduction (subgroup with baseline increased C-210 reactive protein), but these results were removed in the final published version of the 211 manuscript (27,31). This was requested by editors and reviewers from the British Medical 212 213 Journal (open review) where the final version was published because this was not prespecified in the study protocol. In addition, they were concerned about the justification of including 214 these secondary outcomes results and post-hoc analysis from under-powered sample size (due 215 216 to early termination). This is surprising since a lack of power may be associated with a risk of not finding a difference when there is one, but not with a risk of finding a difference when 217 218 there is none. None of these RCTs reported a significant deleterious effect.

219

### 220 Effect of chloroquine derivatives without azithromycin

As several studies addressed the effectiveness of the combination of chloroquine derivatives

with a macrolide, specifically AZ, we tested if the favorable clinical effect (observed in

223 clinical studies) remained after exclusion of comparisons with combination therapy

(Supplementary Figure 1). A favorable effect was still observed for duration of cough (n = 1, n)

point estimate 0.12, p = .001), duration of fever (n = 2, 0.05, p = .002), clinical cure (n = 2, 0.05, p = .002)

226 0.48, p = .022), C-reactive protein levels (n = 1, 0.55, p = .045), interleukin-6 levels (n = 1,

227 0.43, p = .002), and death (n= 3, 0.31,  $p \le .001$ ). Interestingly, the effect was not significant

anymore for persistent viral shedding (n = 7, 0.51, 0.20-1.33, p = 0.17).

#### 230 Outcomes with a significant summary effect in clinical studies

231	We found a favorable summary effect on duration of cough ( $n = 2$ , point estimate 0.19, 95%)
232	confidence interval 0.09-0.42, $p = .00003 - I^2 = 0\%$ ), duration of fever (n = 3, 0.11, 0.01-0.90,
233	p=.039 – $I^2$ = 91%, p < .001), clinical cure (n = 3, 0.21, 0.05-1.0, p = .0495 – $I^2$ = 81%, p <
234	.001), and death (n = 4, 0.32, 0.19-0.52, p = 4.1 x $10^{-6} - I^2 = 0\%$ , p = .71 – Table S9). A trend
235	for the outcome "death or ICU transfer" was also noted (n = 3, 0.29, 0.08-1.10, p = $.069 - I^2 =$
236	85%, p < .002) with a point estimate very similar to that observed for the death outcome (0.3,
237	e.g. a 3 fold decrease in the risk of ICU transfer and/or death). For persistent viral shedding,
238	10 comparisons were included with a significant favorable effect on persistent viral shedding
239	(n = 10, point estimate 0.43, 0.20-0.92, p = $.031 - I^2 = 75\%$ , p < $.001$ ).

240

### 241 **Discussion**

Chloroquine derivatives present a paradox. On one hand, the heterogeneity of patients and 242 243 treatment schemes make it difficult to obtain a clear picture while the epidemic is still 244 ongoing. On the other hand, despite controversy, only chloroquine derivatives have been used by physicians on a large-scale basis as treatment for COVID-19 (36). According to the Sermo 245 Real Time Covid-19 Barometer (https://www.sermo.com/, consulted 27 May), for over 246 20,000 physicians across 30 countries, chloroquine derivatives are the first medication used to 247 treat COVID-19 patients in ICUs (43% - except oxygen, anti-clotting / anticoagulants, 248 249 steroids and norepinephrine) and in other hospital settings (52% - except oxygen), and the second in outpatient settings (33%, after AZ and similar antibiotics). 250 Indeed, we were challenged by the major discrepancies between the results of the 251 252 various published studies and our experience at the IHU where 7800 ECGs were performed in 4000 patients. In order to understand which elements could lead to contradictory results, we 253

compared the results of studies carried out by clinicians (real world) and those carried out by 254 255 database analysts (virtual world of big data - Figure 1). The clinical studies used a standardized treatment protocol with methods that included assessment of contraindications, 256 daily dosage, adjuvant measures and duration of treatment with at least 48 hours of treatment 257 before the objective could be assessed. For example, assessment of kalemia and 258 electrocardiogram is critical prior to treatment, especially when the chloroquine derivative is 259 combined with AZ (37). At the same time, we observed that virtual big data studies did not 260 mention these elements and considered the presence of chloroquine derivative prescription in 261 electronic records in a binary fashion. Obviously, the number of patients included in the 262 database analyses was much higher than the number of patients included in the clinical 263 studies, because these databases are made up of thousands of electronic medical records 264 (EMR). As mentioned in the past (4), this type of studies have tremendous statistical power 265 266 but are limited by clinical inaccuracy that makes their conclusions difficult to believe. As a matter of fact, we cannot believe that in some series there is up to 8% of deaths 267 268 due to cardiac rhythm disorders (18), whereas all the electrocardiograms performed in the IHU (our center) for 4000 patients and analyzed by a team of cardiologists specializing in 269 rhythmology have not seen any, except for an increase in QTc which justified stopping 270 treatment in only 3 cases (38). Under these conditions we thought that people who really 271 272 observed the patients had a very different perception of the results from people who had not observed the patients but retained observations. The major elements of this study are that, 273 overall there is an extremely significant difference between the analyses of data not collected 274 275 directly by the doctors who cared patients and the studies carried out by the physicians who set up these studies and cared patients, including the randomized studies. The second thing is 276 277 that in these studies conducted electronically, the treatment is never really specified, with the dosage and duration of treatment making it impossible to assess efficacy (dose too low) or 278

toxicity (dose too high). In addition to this major bias, we also noted a significant bias when
the authors had conflicts of interest due to their relationship with industrialists trying to
market molecules in the same therapeutic framework competing with HCQ.

For discrepancies in published data, favorable evidence for chloroquine derivatives is sometimes censored by the journal (open review of Tang's randomized controlled trial, published in the British Medical Journal (27,30,31)). For the article by Mahevas *et al.* (29), one of us (DR) had contact with one of the authors (B Godeau) who told him that it was the methodologist (P Ravaud) who did not want to carry out the statistical tests demonstrating the superiority of dual therapy over the control group (death or transfer to ICU, 0/15 versus 16/63, bilateral Mid-P exact test p = .02).

Overall, and as previously published, the relevance of the analysis of important 289 medical data depends on clinical accuracy (4). Indeed, the discrepancy between clinicians and 290 291 epidemiologists reflects a major trend, that of the analysis of large medical data, with database warehouse more or less well filled by individuals who are not directly included in the work 292 293 reported. This analysis is unrelated to the observations made by physicians who are in direct 294 contact with patients and which lead to divergent interpretations and opposite conclusions, which are of real interest and show that the world predicted by Baudrillard (39); that of a 295 parallel world of numerical analysis completely disconnected from reality; is being born. 296

Under these conditions, a meta-analysis allowing for the combination of different studies makes it possible to identify a general trend. This makes it possible to reconcile the chloroquine derivative efficacy that many doctors have perceived with the results of the first published studies. This meta-analysis is based on several studies, including four RCTs, and identifies a favorable trend toward the benefit of chloroquine derivatives in the treatment of COVID-19 patients, enabling us to make a grade I recommendation for its use against the disease.

304	Re	References			
305	1.	Muchielli L. Le blog de Laurent Mucchielli. Accessed May 23, 2020 at			
306		https://blogs.mediapart.fr/laurent-mucchielli/blog			
307	2.	Lagier JC, Million M, Raoult D. Bouillabaisse or Fish Soup: The Limitations of			
308		Meta-analysis Confronted to the Inconsistency of Fecal Microbiota Transplantation			
309		Studies. Clin Infect Dis. 2020 May 23;70(11):2454. doi: 10.1093/cid/ciz707.			
310	3.	Lagier JC, Aubry C, Delord M, Michelet P, Tissot-Dupont H, Million M, Brouqui P,			
311		Raoult D, Parola P. From Expert Protocols to Standardized Management of Infectious			
312		Diseases. Clin Infect Dis. 2017 Aug 15;65(suppl_1):S12-S19. doi:			
313		10.1093/cid/cix403. PMID: 28859349			
314	4.	Million M, Raoult D. Relevance of Medical Big Data Analysis Depends on Clinical			
315		Accuracy: The Q Fever Paradigm. Clinical Infectious Diseases, Volume 68, Issue 1, 1			
316		January 2019, Pages 169–170, https://doi.org/10.1093/cid/ciy533			
317	5.	Melenotte C, Protopopescu C, Million M, Edouard S, Carrieri MP, Eldin C, Angelakis			
318		E, Djossou F, Bardin N, Fournier PE, Mège JL, Raoult D. Clinical Features and			
319		Complications of Coxiella burnetii Infections From the French National Reference			
320		Center for Q Fever. JAMA Netw Open. 2018 Aug 3;1(4):e181580. doi:			
321		10.1001/jamanetworkopen.2018.1580. PMID: 30646123			
322	6.	Lagier JC, Fenollar F, Lepidi H, Roch G, Million M, Raoult D. Treatment of Classic			
323		Whipple's Disease: From in Vitro Results to Clinical Outcome. J Antimicrob			
324		Chemother. 2014 Jan;69(1):219-27. oi: 10.1093/jac/dkt310. Epub 2013 Aug 14.			
325	7.	Yanturali S, Aksay E, Demir OF, Atilla R. Massive hydroxychloroquine overdose.			
326		Acta Anaesthesiol Scand. 2004 Mar;48(3):379-81. doi: 10.1111/j.0001-			
327		5172.2004.0302.x.			

328	8.	Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, Mourão
329		MPG, Brito-Sousa JD, Baía-da-Silva D, Guerra MVF, Hajjar LA, Pinto RC, Balieiro
330		AAS, Pacheco AGF, Santos JDO Jr, Naveca FG, Xavier MS, Siqueira AM,
331		Schwarzbold A, Croda J, Nogueira ML, Romero GAS, Bassat Q, Fontes CJ,
332		Albuquerque BC, Daniel-Ribeiro CT, Monteiro WM, Lacerda MVG; CloroCovid-19
333		Team. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive
334		Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome
335		Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw
336		Open. 2020 Apr 24;3(4):e208857. doi: 10.1001/jamanetworkopen.2020.8857.
337	9.	Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a
338		treatment of COVID-19: results of an open-label non-randomized clinical trial
339		[published online ahead of print, 2020 Mar 20]. Int J Antimicrob Agents.
340		2020;105949. doi:10.1016/j.ijantimicag.2020.105949
341	10	. Andreani J, Le Bideau M, Duflot I, Jardot P, Rolland C, Boxberger M, Wurtz N,
342		Rolain JM, Colson P, La Scola B, Raoult D. In vitro testing of combined
343		hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect.
344		Microb Pathog. 2020 Apr 25;145:104228. doi: 10.1016/j.micpath.2020.104228.
345		Online ahead of print.
346	11	. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-
347		Analysis. 2009. John Wiley & Sons, Ltd. 2009.
348		https://doi.org/10.1002/9780470743386.
349	12	. Barbosa J, Kaitis D, Freedman R, Le K, Lin X. Clinical outcomes of
350		hydroxychloroquine in hospitalized patients with COVID-19: a quasi-randomised
351		comparative study. Submitted to New Eng J Med.
352		https://www.dropbox.com/s/urzapkyij542qx5/NEJM_Clinical%20Outcomes%20of%2

353 0Hydroxychlorquine%20in%20Patients%20with%20COVID19.pdf.pdf.pdf.pdf.pdf.pdf
354 f.pdf.pdf?dl=0

355	13. Carlucci P, Ahuja T, Petrilli CM, Rajagopalan H, Jones S, Rahimian J.
356	Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and
357	azithromycin alone: outcomes in hospitalized COVID-19 patients. medRxiv
358	2020.05.02.20080036; doi: https://doi.org/10.1101/2020.05.02.20080036
359	14. Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, et al. A pilot study of hydroxychloroquine
360	in treatment of patients with common coronavirus disease-19 (COVID-19). J Zhejiang
361	Unniv (Med Sci) 2020;49:0.
362	15. Guerin V, Lardenois T, Levy P, Regensberg de Andreis N, Sarrazin E, Thomas JL,
363	Wonner M. Covid-19: Etude rétrospective chez 88 sujets avec 3 approches
364	thérapeutiques différentes (traitement symptomatique / azithromycine / azithromycine
365	+ hydroxychloroquine). Rapport d'expérience de médecins de terrain
366	Recommandations diagnostiques et thérapeutiques à l'usage de leurs consoeurs et
367	confrères. Available online at : https://stopcovid19.today/wp-
368	content/uploads/2020/04/COVID_19_RAPPORT_ETUDE_RETROSPECTIVE_CLI
369	NIQUE_ET_THERAPEUTIQUE_200430.pdf
370	16. Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in
371	Hospitalized Patients with Covid-19 [published online ahead of print, 2020 May 7]. N
372	Engl J Med. 2020;10.1056/NEJMoa2012410. doi:10.1056/NEJMoa2012410
373	17. Magagnoli J, Narendran S, Pereira F, Cummings T, Hardin JW, Sutton SS, Ambati J.
374	Outcomes of hydroxychloroquine usage in United States veterans hospitalized with
375	Covid-19. medRxiv 2020.04.16.20065920;
376	https://doi.org/10.1101/2020.04.16.20065920

377	18	. Mehra RM, Desai SS, Ruschitzka F, Patel AN, Hydroxychloroquine or chloroquine
378		with or without a macrolide for treatment of COVID-19: a multinational registry
379		analysis. The Lancet. Published Online May 22, 2020 https://doi.org/10.1016/S0140-
380		6736(20)31180-6
381	19	. Singh S, Ahmad Khan A, Monica Chowdhry M, Arka Chatterjee A. Outcomes of
382		Hydroxychloroquine Treatment Among Hospitalized COVID-19 Patients in the
383		United States- Real-World Evidence From a Federated Electronic Medical Record
384		Network. medRxiv 2020.05.12.20099028; doi:
385		https://doi.org/10.1101/2020.05.12.20099028
386	20	. Rosenberg E, Dufort E, Udo T, et al. Association of Treatment With
387		Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With
388		COVID-19 in New York State. JAMA. Published online May 11, 2020.
389		doi:10.1001/jama.2020.8630
390	21	. Barbosa Esper R, Souza da Silva R, Teiichi Costa Oikawa F, Machado Castro M,
391		Razuk-Filho A, Benedito Batista Junior P , Lotze SW , Nunes da Rocha C, de Sá
392		Cunha Filho R, Barbosa de Oliveira SE, Ribeiro PL, Vigar Martins VC, Silva Braga
393		Bueno F, Ligeiro Gonçalves Esper P , Fagundes Parrillo E. Empirical treatment with
394		hydroxychloroquine and azithromycin for suspected cases of COVID-19 followed-up
395		by telemedicine.
396		https://www.dropbox.com/s/5qm58cd4fneeci2/2020.04.15%20journal%20manuscript
397		%20final.pdf?dl=0.
398	22	. Davido B, Lansaman T, Bessis S, Hydroxychloroquine plus azithromycin: a potential
399		interest in reducing in-hospital morbidity due to COVID-19 pneumonia (HI-ZY-
400		COVID)? Posted May 11, 2020, https://doi.org/10.1101/2020.05.05.20088757,
401		https://www.medrxiv.org/content/10.1101/2020.05.05.20088757v1

402	23. Kim MS, Jang SW, Park YK et al, Treatment Response to Hydroxychloroquine,
403	Lopinavir/Ritonavir, and Antibiotics for Moderate COVID 19: A First Report on the
404	Pharmacological Outcomes from South Korea, medRxiv 2020.05.13.20094193.
405	https://doi.org/10.1101/2020.05.13.20094193.
406	https://www.medrxiv.org/content/10.1101/2020.05.13.20094193v1
407	24. Shabrawishi MH, Naser AY, Aldobyany AM, Negative nasopharyngeal SARS-CoV-2
408	PCR conversion in Response to different therapeutic interventions, Posted May 11,
409	2020. https://doi.org/10.1101/2020.05.08.20095679
410	https://www.medrxiv.org/content/10.1101/2020.05.08.20095679v1
411	25. Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, Zhuang R, Hu B, Zhang Z. 2020.
412	Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized
413	clinical trial. medRxiv 2020.03.22.20040758;
414	https://doi.org/10.1101/2020.03.22.20040758
415	26. Huang M, Tang T, Pang P, Li M, Ma R, Lu J, Shu J, You Y, Chen B, Liang J, Hong Z,
416	Chen H, Kong L, Qin D, Pei D, Xia J, Jiang S, Shan H. Treating COVID-19 with
417	Chloroquine. 2020. J Mol Cell Biol. In press. https://doi.org/10.1093/jmcb/mjaa014.
418	27. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, Wu Y, Xiao W, Liu S, Chen E,
419	Chen W, Wang X, Yang J, Lin J, Zhao Q, Yan Y, Xie Z, Li D, Yang Y, Liu L, Qu J,
420	Ning G, Shi G, Xie Q. 2020. Hydroxychloroquine in patients with COVID-19: an
421	open-label, randomized, controlled trial. medRxiv 2020.04.10.20060558;
422	https://doi.org/10.1101/2020.04.10.20060558
423	28. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, Wang Q, Miao H.
424	Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive
425	study. Signal Transduct Target Ther. 2020 Mar 27;5(1):33.
426	https://doi.org/10.1038/s41392-020-0148-4.

427	29. Mahevas M, Tran VT, Roumier M, Chabrol A, Paule R, Guillaud C, Gallien S,
428	Lepeule R, Tali Szwebel TA, Lescure X, Schlemmer F, Matignon M, Khellaf M,
429	Crickx E, Terrier B, Morbieu C, Legendre P, Dang J, Schoindre Y, Pawlotski JM,
430	Michel M, Perrodeau E, Carlier N, Roche N, De Lastours V, Mouthon L, Audureau E,
431	Ravaud P, Godeau B, Costedoat N. No evidence of clinical efficacy of
432	hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen
433	requirement: results of a study using routinely collected data to emulate a target trial.
434	2020. medRxiv 2020.04.10.20060699; https://doi.org/10.1101/2020.04.10.20060699
435	30. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, Wu Y, Xiao W, Liu S, Chen E,
436	Chen W, Wang X, Yang J, Lin J, Zhao Q, Yan Y, Xie Z, Li D, Yang Y, Liu L, Qu J,
437	Ning G, Shi G, Xie Q. 2020. Hydroxychloroquine in patients with COVID-19: an
438	open-label, randomized, controlled trial. medRxiv 2020.04.10.20060558; Version 1
439	(initial preprint) accessed on 2020, May, 27 at :
440	https://www.medrxiv.org/content/10.1101/2020.04.10.20060558v1?versioned=true
441	31. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, Wu Y, Xiao W, Liu S, Chen E,
442	Chen W, Wang X, Yang J, Lin J, Zhao Q, Yan Y, Xie Z, Li D, Yang Y, Liu L, Qu J,
443	Ning G, Shi G, Xie Q. Hydroxychloroquine in patients with mainly mild to moderate
444	coronavirus disease 2019: open label, randomised controlled trial BMJ 2020; 369
445	:m1849. https://doi.org/10.1136/bmj.m1849
446	32. Ashraf AA, Shokouhi N, Shirali E, et al. COVID-19 in Iran, a comprehensive
447	investigation from exposure to treatment outcomes. medRxiv.
448	https://doi.org/10.1101/2020.04.20.20072421
449	https://www.medrxiv.org/content/10.1101/2020.04.20.20072421v1
450	33. Huang M, Li M, Xiao F, Liang J, Pang P, Tang T, Liu S, Chen B, Shu J, You Y, Li Y,
451	Tang M, Zhou J, Jiang G, Xiang J, Hong W, He S, Wang Z, Feng J, Lin C, Ye Y, Wu

452	Z, Li Y, Zhong B, Sun R, Hong Z, Liu J, Chen H, Xiaohua Wang, Zhonghe Li, Pei D,
453	Tian L, Xia J, Jiang S, Zhong N, Shan H. Preliminary evidence from a multicenter
454	prospective observational study of the safety and efficacy of chloroquine for the
455	treatment of COVID-19. medRxiv 2020.04.26.20081059;
456	https://doi.org/10.1101/2020.04.26.20081059
457	34. Membrillo de Novales FJ, Ramírez-Olivencia G, Estébanez M, de Dios B, Herrero
458	MD, Mata T, Borobia AM, Gutiérrez C, Simón M, Ochoa A, Martínez Y, Aguirre A,
459	Alcántara FDA, Fernández-González P, López E, Campos S, Navarro M, Ballester
460	LE. Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-
461	19 Patients: An Observational Study. Preprints 2020, 2020050057 (doi:
462	10.20944/preprints202005.0057.v1).
463	35. Yu B, Wang W, Li C, Hydroxychloroquine application is associated with a decreased
464	mortality in critically ill patients with COVID-19, Posted May 01, 2020.
465	https://doi.org/10.1101/2020.04.27.20073379,
466	https://www.medrxiv.org/content/10.1101/2020.04.27.20073379v1
467	36. Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. 2020. Chloroquine and
468	hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob
469	agents. In press. https://doi.org/10.1016/j.ijantimicag.2020.105932
470	37. Million M, Lagier JC, Gautret P, Colson P, Fournier PE, Amrane S, Hocquart M,
471	Mailhe M, Esteves-Vieira V, Doudier B, Aubry C, Correard F, Giraud-Gatineau A,
472	Roussel Y, Berenger C, Cassir N, Seng P, Zandotti C, Dhiver C, Ravaux I, Tomei C,
473	Eldin C, Tissot-Dupont H, Honoré S, Stein A, Jacquier A, Deharo JC, Chabrière E,
474	Levasseur A, Fenollar F, Rolain JM, Obadia Y, Brouqui P, Drancourt M, La Scola B,
475	Parola P, Raoult D. Early treatment of COVID-19 patients with hydroxychloroquine
476	and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel

477	Med Infect Dis. 2020 May 5:101738. doi: 10.1016/j.tmaid.2020.101738. Online ahead
478	of print.

479	38. Lagier JC, Million M, Gautret P, Colson P, Cortaredona S, Giraud-Gatineau A,
480	Honoré S, Gaubert JY, Fournier PE, Tissot-Dupont H, Chabriere E, Stein A, Deharo
481	JC, Fenollar F, Rolain JM, Obadia Y, Jacquier A, La Scola B, Brouqui P, Drancourt
482	M, Parola P, Raoult D. Early diagnosis and management of COVID-19 patients: a
483	real-life cohort study of 3,737 patients, Marseille, France. Submitted.
484	39. Baudrillard J. Simulacres et Simulation. Editions Galilée, Paris, France. 1981.

## 486 Funding

487 This work was funded by ANR-15-CE36-0004-01 and by ANR "Investissements d'avenir",

488 Méditerranée infection 10-IAHU-03, and was also supported by Région Provence-Alpes-Côte

- 489 d'Azur. This work had received financial support from the Mediterranean Infection
- 490 Foundation.
- 491

# 492 **Declaration of competing interest**

493 The authors declare no competing interests. Funding sources had no role in the design and

494 conduct of the study; collection, management, analysis, and interpretation of the data; and

495 preparation, review, or approval of the manuscript. Our group used widely available generic

496 drugs distributed by many pharmaceutical companies.

497

### 498 Acknowledgments

499 We thank Christian Devaux for helpful interactions and Fanyu Huang for Chinese to English

500 translation of the study by Chen J *et al.* (14).


501	<b>Figure</b>	legends
-----	---------------	---------

- 502 Figure 1. Unsupervised analysis evidencing an association between big data studies, inaccurate
- 503 treatment protocol, conflict of interest and absence of beneficial effect of chloroquine derivative
- 504 RCT: randomized controlled trial (hatched lines), Pro : study reporting a favourable effect of
- 505 chloroquine derivative, Con: study that report no or deleterious effet, Clinical : study performed by
- 506 physician who take care of patients, Big data: study performed by specialists in data analysis who do
- 507 not take care of patients, Detailed treatment: therapeutic protocol detailed in the method with dosage
- 508 for 48 hours before outcome assessment. Three among four RCTs found a beneficial effect.

```
510 Figure 2. Forest plot of meta-analysis on the effect of chloroquine derivatives in COVID-19
```

#### 511 infected patients

- 512 CI: confidence interval, ICU: intensive care unit, CT-scan: computed tomography scanner, HCQ:
- 513 hydroxychloroquine, CQ: chloroquine, AZ: azithromycin, RCT: randomized controlled trial, (H)CQ:
- 514 chloroquine derivatives (hydroxychloroquine (HCQ) or chloroquine (CQ)).



		Outcome	Country	Study name	Statistics for each study			r each study	Odds ratio and 95% Cl
					Odds	Lower	Upper		
					ratio	limit		p-Value	
	/	K. Death or ICU transfer	Iran	Ali Ashraf, MedRxiv, 2020	0.04	0.01	0.17	0.000031	
		A. Hospitalization rate	Brazil	Barbosa Esper, 2020	0.35	0.14	0.87	0.023675	
		I. Aggravation to severe	China	Chen, J Zheijang Univ, 2020 RCT	3.21	0.12	85.20	0.486189	
		H. Thoracic CT-scan imaging	China	Chen, J Zheijang Univ, 2020 RCT	1.75	0.40	7.66	0.457708	
		N. Persistent viral shedding	China	Chen, J Zheijang Univ, 2020 RCT	2.15	0.17	26.67	0.550103	
		I. Aggravation to severe	China	Chen, MedRxiv, 2020 RCT	0.10	0.00	1.88	0.123172	<u> </u>
		H. Thoracic CT-scan imaging	China	Chen, MedRxiv, 2020 RCT	0.29	0.09	0.91	0.033657	
		C. Duration of fever	China	Chen, MedRxiv, 2020 RCT	0.14	0.04	0.46	0.001441	
		B. Duration of cough	China	Chen, MedRxiv, 2020 RCT	0.13	0.03	0.45	0.001493	
		K. Death or ICU transfer	France	Davido, MedRxiv, 2020	0.41	0.21	0.80	0.008863	
		N. Persistent viral shedding	France	Gautret, Int J Antimicrob Agents, 2020 with AZ	0.01	0.00	0.32	0.007603	
		N. Persistent viral shedding	France	Gautret, Int J Antimicrob Agents, 2020 without AZ	0.11	0.02	0.66	0.016207	
		L. Death	France	Guerin, 2020	0.54	0.02	14.01	0.713884	<
		D. Clinical cure	France	Guerin, 2020	0.06	0.02	0.18	0.000001	
		D. Clinical cure	China	Huang, J Mol Cell Biol, 2020 RCT	0.35	0.05	2.41	0.285921	
		M. Length of hospital stay	China	Huang, J Mol Cell Biol, 2020 RCT	0.05	0.00	0.99	0.049526	
		H. Thoracic CT-scan imaging	China	Huang, J Mol Cell Biol, 2020 RCT	0.13	0.01	2.84	0.194431	
		N. Persistent viral shedding	China	Huang, J Mol Cell Biol, 2020 RCT	0.37	0.01	9.98	0.550511	
	1	N. Persistent viral shedding	China	Huang, MedRxiv, 2020	0.13	0.07	0.25	0.000000	
	1	C. Duration of fever	China	Huang, MedRxiv, 2020 (moderate subgroup)	0.02	0.01	0.06	0.000000	
	/	M. Length of hospital stay	China	Huang, MedRxiv, 2020 (moderate subgroup)	0.73	0.50	1.07	0.109735	
al .	{	I. Aggravation to severe	China	Huang, MedRxiv, 2020 (moderate subgroup)	0.14	0.02	1.15	0.067647	
	1	H. Thoracic CT-scan imaging	China	Huang, MedRxiv, 2020 (Sun Yat-Sen subgroup)	0.89	0.30	2.61	0.830039	
	1	N. Persistent viral shedding	South Korea	Kim, MedRxiv, 2020	0.24	0.09	0.65	0.004518	
		M. Length of hospital stay	South Korea	Kim, MedRxiv, 2020	0.29	0.11	0.77	0.013181	
		C. Duration of fever	South Korea	Kim, MedRxiv, 2020	0.57	0.22	1.48	0.250698	
		B. Duration of cough	South Korea	Kim, MedRxiv, 2020	0.25	0.09	0.66	0.005282	
		L. Death	France	Mahevas, MedRxiv, 2020	0.72	0.16	3.30	0.668282	
		K. Death or ICU transfer	France	Mahevas, Medixiv, 2020 Mahevas, Medixiv, 2020	0.90	0.44	1.85	0.766230	
		L Aggravation to severe	France	Mahevas, Medixiv, 2020 Mahevas, Medixiv, 2020	1.24	0.63	2.42	0.531288	
		L Death	Spain	Membrillo, Preprints, 2020	0.29	0.03	0.61	0.001115	
		M. Length of hospital stay	Spain	Membrillo, Preprints, 2020	1.45	0.77	2.72	0.249268	
		N. Persistent viral shedding	Saudi Arabia	Shabrawishi, MedRxiv, 2020 - HCQ/CQ + AZ	1.45	0.42	2.40	1.000000	
		N. Persistent viral shedding	Saudi Arabia Saudi Arabia	Shabrawishi, MedRxiv, 2020 - HCQ/CQ + AZ Shabrawishi, MedRxiv, 2020 - HCQ/CQ	1.00	0.42	2.40	1.000000	
		N. Persistent viral shedding N. Persistent viral shedding	Saudi Arabia Saudi Arabia	Shabrawishi, MedRxiv, 2020 - HCQ/CQ Shabrawishi, MedRxiv, 2020 - HCQ/CQ + antivirals	1.00	0.35	2.86 9.88	0.470789	
		N. Persistent viral shedding N. Persistent viral shedding	Saudi Arabia China	Shabrawishi, Medikxiv, 2020 - HCQ/CQ + antivirais Tang, Medikxiv, 2020 RCT	0.75	0.35	9.88	0.339175	
		N. Persistent viral shedding D. Clinical cure	China	Tang, MedRxiv, 2020 RCT	0.75	0.42	0.97	0.039175	
		F. C-reactive protein	China	Tang, MedRxiv, 2020 RCT	0.50	0.26	0.97	0.039559	
		E. Lymphocyte count L. Death	China China	Tang, MedRxiv, 2020 RCT	0.84	0.47	1.49 0.58	0.546320 0.000647	
	1	L. Death G. Interleukin-6		Yu, MedRxiv, 2020a					
		G. Interleukin-6	China	Yu, MedRxiv, 2020b	0.43	0.25	0.73	0.001991	
	(				0.38	0.28	0.52	0.000000	
		K. Death or ICU transfer	USA	Geleris, NEIM, 2020	1.00	0.82	1.22	1.000000	
	1								
	1	I. Aggravation to severe L. Death	USA USA	Magagnoli, MedRxiv, 2020	0.88	0.53	1.45 1.36	0.610951 0.000000	
				Mehra, Lancet, 2020 - CQ + Macrolide	1.28	1.21			
	1	L. Death	USA	Mehra, Lancet, 2020 - CQ alone	1.25	1.15	1.36	0.000000	
ata	)	L. Death	USA	Mehra, Lancet, 2020 - HCQ + Macrolide	1.35	1.28	1.41	0.000000	
	7	L. Death	USA	Mehra, Lancet, 2020 - HCQ alone	1.24	1.16	1.32	0.000000	
	1	L. Death	USA	Rosenberg, JAMA, 2020 - HCQ alone	1.04	0.76	1.44	0.789895	
		L. Death	USA	Rosenberg, JAMA, 2020 - HCQ-AZ	1.15	0.88	1.51	0.309873	
	1	L. Death	USA	Singh, MedRxiv, 2020a	0.95	0.71	1.26	0.715438	
	1	J. Ventilation	USA	Singh, MedRxiv, 2020b	0.80	0.53	1.19	0.265330	
					1.20	1.13	1.29	0.000000	

Clinica

Big dat

Favours (H)CQ

0.1

0.2

0.5 1

5 Favours No (H)CQ

2